Holen Sie sich die Stockscreener-App
152.56
0.44%
0.6613
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech Inc. Stock Analysis and ForecastFree Stock Movement Tracking - jammulinksnews.com
What analysts say about Krystal Biotech Inc. stockFast-track wealth growth - jammulinksnews.com
What drives Krystal Biotech Inc. stock priceRapidly growing investment returns - jammulinksnews.com
Is Krystal Biotech Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
What makes Krystal Biotech Inc. stock price move sharplyTop Gaining Low Risk Assets - Newser
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Nisa Investment Advisors LLC - Defense World
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Hedge Fund and Insider Trading News: Bobby Jain, Bill Ackman, Ken Griffin, Sylebra Capital Management, Millennium Management, Krystal Biotech Inc (KRYS), and More - Insider Monkey
William Blair Predicts Lower Earnings for Krystal Biotech - Defense World
Krishnan Krish S, Krystal Biotech CEO, sells $5.39 million in stock - Investing.com Canada
Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock By Investing.com - Investing.com South Africa
Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock - Investing.com Australia
Citi Maintains Krystal Biotech(KRYS.US) With Hold Rating, Raises Target Price to $176 - 富途牛牛
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Trimmed by Bank of New York Mellon Corp - Defense World
why krystal biotech inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
M&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech FY2025 EPS Estimate Lowered by William Blair - Defense World
Why Krystal Biotech Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
How Krystal Biotech Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
Teacher Retirement System of Texas Has $1.05 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Forecasts Lower Earnings for Krystal Biotech - Defense World
William Blair Expects Lower Earnings for Krystal Biotech - Defense World
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up - Yahoo Finance
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK By Investing.com - Investing.com South Africa
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK - Investing.com Nigeria
Transcript : Krystal Biotech, Inc.Special Call - MarketScreener
Krystal Biotech Begins Phase 1/2 Trial for KB801 - TipRanks
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - The Manila Times
Krystal Biotech Initiates First Patient Dosing in Phase 1/2 EMERALD-1 Trial for KB801 in Neurotrophic Keratitis - Nasdaq
Revolutionary Eye Drop Gene Therapy: Krystal Biotech Targets 68,000 Patient NK Market in New Trial - Stock Titan
New York State Teachers Retirement System Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Allspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
4.50%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):